Previous Close | 65.27 |
Open | 65.50 |
Bid | 65.37 x 800 |
Ask | 65.50 x 800 |
Day's Range | 64.64 - 66.35 |
52 Week Range | 64.64 - 87.87 |
Volume | |
Avg. Volume | 7,349,480 |
Market Cap | 81.577B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 14.54 |
EPS (TTM) | 4.50 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | 3.08 (4.72%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | 83.88 |
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Q1 2024 Gilead Sciences Inc Earnings Call